DiCE gets its 'library' card ready as it speeds development of DNA database-derived molecules with more investor cash

Investors like to see big plans, and Kevin Judice has plenty. The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.

On Friday, those big plans landed him an $80 million Series C round.